Forma Therapeutics Holdings, Inc (FMTX)

Etorro trading 970x250
Forma Therapeutics Holdings, Inc (FMTX) Logo

About Forma Therapeutics Holdings, Inc

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts. Address: 500 Arsenal Street, Watertown, MA, United States, 02472

Forma Therapeutics Holdings, Inc News and around…

Latest news about Forma Therapeutics Holdings, Inc (FMTX) common stock and company :

Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee
13 Jan, 2022 FinancialContent

Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee

Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
07 Jan, 2022 FinancialContent

Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 277% to Reach the Level Wall Street Analysts Expect?
30 Dec, 2021 Yahoo! Finance

The mean of analysts' price targets for Forma Therapeutics Holdings, Inc. (FMTX) points to a 277.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Forma Therapeutics (FMTX) Sees Hammer Chart Pattern: Time to Buy?
28 Dec, 2021 Yahoo! Finance

Forma Therapeutics (FMTX) has been struggling lately, but the selling pressure may be coming to an end soon.

Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia
16 Dec, 2021 FinancialContent

Forma's Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia

Forma's (FMTX) Etavopivat Proves Safety Profile in SCD Study
13 Dec, 2021 Yahoo! Finance

Forma's (FMTX) investigational PKR activator, etavopivat significantly improves anemia and red blood cell health in patients with sickle cell disease.

Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease
11 Dec, 2021 FinancialContent

Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease

Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease
09 Dec, 2021 FinancialContent

Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
06 Dec, 2021 FinancialContent

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt ...

 Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
30 Nov, 2021 FinancialContent

Forma Therapeutics Appoints Acclaimed Global Sickle Cell Disease Leader, Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer

Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
30 Nov, 2021 Yahoo! Finance

WATERTOWN, Mass., November 30, 2021--Forma Therapeutics Appoints Acclaimed Global Sickle Cell Disease Leader, Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer

Bolt Biotherapeutics Announces Changes to its Board of Directors
19 Nov, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointments of Brian O’Callaghan and Frank D. Lee to the Board of Directors. With these additions, longtime Director Peter Moldt, Ph.D. is stepping down from the Board of Directors and

Could The Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Ownership Structure Tell Us Something Useful?
19 Nov, 2021 Yahoo! Finance

If you want to know who really controls Forma Therapeutics Holdings, Inc. ( NASDAQ:FMTX ), then you'll have to look at...

How Much Upside is Left in Forma Therapeutics Holdings, Inc. (FMTX)? Wall Street Analysts Think 185%
18 Nov, 2021 Yahoo! Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 184.6% in Forma Therapeutics Holdings, Inc. (FMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

VBR's Underlying Holdings Could Mean 11% Gain Potential
15 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Value ETF (VBR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $205.86 per unit.

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
12 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its ...

Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
12 Nov, 2021 FinancialContent

Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Earnings Scheduled For November 12, 2021
12 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Zevia (NYSE:ZVIA) is estimated to report quarterly loss at $0.43 per share on ...

Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
05 Nov, 2021 FinancialContent

Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021

Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
04 Nov, 2021 FinancialContent

Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting

Mission BioCapital Announces $275 Million Fund V
04 Nov, 2021 FinancialContent

Mission BioCapital Announces $275 million Fund V; adds Michael D. Taylor, Ph.D., and Steve Tregay, Ph.D., as partners

First Week of FMTX December 17th Options Trading
25 Oct, 2021 FinancialContent

Investors in Forma Therapeutics Holdings Inc (FMTX) saw new options begin trading this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FMTX options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

How The Pieces Add Up: IWV Targets $293
15 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 3000 ETF (IWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $293.18 per unit.

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

45 Biggest Movers From Yesterday
08 Oct, 2021 FinancialContent

Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
07 Oct, 2021 FinancialContent

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced positive initial results from a Phase 1 trial of its novel CBP/p300 inhibitor, the oral small molecule FT-7051, in men with metastatic castration-resistant prostate cancer (mCRPC). Initial clinical data from the Courage Study, an ongoing first-in-human Phase 1 trial presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, showed an encouraging safety profile of FT-7051, as well as high specificity to the CBP/p300 pathway.

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
03 Oct, 2021 FinancialContent

Biotech stocks came under pressure in the week endingOct. 1, dragged by broader market weakness and the selling ofvaccine ...

Forma Therapeutics to Participate in Upcoming Investor Conferences
17 Sep, 2021 FinancialContent

Forma Therapeutics to Participate in Upcoming Investor Conferences.

Forma Therapeutics Holdings, Inc (FMTX) is a NASDAQ Common Stock listed in , ,

970x250